Sanofi gets CDSCO marketing nod for RSV treatment Beyfortus in India
Drugmaker, Sanofi India, has received marketing authorisation approval from the Central Drugs Standard Control Organisation (CDSCO) for Beyfortus in India.
Beyfortus is used for the prevention of Respiratory Syncytial Virus (RSV) and Lower Respiratory Tract Disease (LRTD) in newborns and infants.
It is also administered to children up to 24 months of age, who remain vulnerable to severe RSV disease through their second RSV season.
RSV is a highly contagious virus that can lead to serious respiratory illness in infants.
"Prevention of RSV in India is still an unmet medical need. This makes the approval of Beyfortus a landmark moment for Sanofi in India," Sanofi Vaccines (India) General Manager Preeti Futnani stated.
In March 2017, Sanofi and AstraZeneca announced an agreement to develop and commercialise Beyfortus.
Under the terms of the agreement, AstraZeneca leads development and manufacturing activities, and Sanofi leads commercialisation activities and records revenues
Read also: Sanofi Healthcare to infuse Euro 400 million in Hyderabad GCC by 2030
